Andere Sprachen Kura Oncology, Inc.

Aktien

A143UH

US50127T1097

KURA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
19,65 ^USD	+3,42 %		+12,09 %	+36,65 %

22.04.	Kura Oncology, Inc. erhält Breakthrough Therapy Designation für Ziftomenib bei NPM1-mutierter AML	CI
14.03.	Transcript : Kura Oncology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kura Oncology to Report First Quarter 2024 Financial Results	25.04.
Sector Update: Health Care Stocks Advance Premarket Monday	22.04.
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy	22.04.
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell	22.04.
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22.04.
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML	22.04.
Kura Oncology to Participate in Stifel Targeted Oncology Forum	10.04.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05.04.
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06.03.
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma	06.03.
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	04.03.
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01.03.
Kura Oncology: Q4 Earnings Snapshot	27.02.
Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results	27.02.
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26.02.
Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia	26.02.
Kura Oncology to Participate in Three Upcoming Investor Conferences	22.02.
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results	20.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kura Oncology, Inc.

Aktien

A143UH

US50127T1097

KURA

Andere Sprachen

Filter